HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goel, A. Articles by Batra, S. K. Search for Related Content PubMed PubMed Citation Articles by Goel, A. Articles by Batra, S. K.

^99mTc-Labeled Divalent and Tetravalent CC49 Single-Chain Fv’s: Novel Imaging Agents for Rapid In Vivo Localization of Human Colon Carcinoma

Department of Biochemistry and Molecular Biology, Department of Radiation Oncology, and Department of Pathology and Microbiology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska; and Coulter Pharmaceutical Inc., San Francisco, California

Radioimmunopharmaceutical agents enabling rapid high-resolution imaging, high tumor-to-background ratios, and minimal immunogenicity are being sought for cancer diagnosis and imaging. Genetic engineering techniques have allowed the design of single-chain Fv’s (scFv’s) of monoclonal antibodies (mAbs) recognizing tumor-associated antigens. These scFv’s show good tumor targeting and biodistribution properties in vivo, indicating their potential as imaging agents when labeled with a suitable radionuclide. Methods: Divalent (sc(Fv)₂) and tetravalent ([sc(Fv)₂]₂) scFv’s of mAb CC49 were evaluated for radioimmunolocalization of LS-174T colon carcinoma xenografts in athymic mice. scFv’s were radiolabeled with ^99mTc by way of the bifunctional chelator succinimidyl-6-hydrazinonicotinate hydrochloride using tricine as the transchelator. The immunoreactivity and in vitro stability of the scFv’s were analyzed after radiolabeling. Biodistribution and pharmacokinetic studies were performed to determine the tumor-targeting potential of the radiolabeled scFv’s. Whole-mouse autoradiography illustrated the possible application of these ^99mTc-labeled multivalent scFv’s for imaging. Results: The radiolabeling procedure gave 95% radiometal incorporation, with a specific activity of >74 MBq/mg scFv. In solid-phase radioimmunoassay, both sc(Fv)₂ and [sc(Fv)₂]₂ exhibited 75%–85% immunoreactivity, with nonspecific binding between 0.8% and 1.2%. Size-exclusion high-performance liquid chromatography showed sc(Fv)₂ as a 60-kDa protein and [sc(Fv)₂]₂ as a 120-kDa protein. Blood clearance studies showed the elimination half-life of ^99mTc-labeled sc(Fv)₂ as 144 min and that of [sc(Fv)₂]₂ as 307 min. Whole-body clearance studies confirmed the rapid elimination of scFv’s, with half-lives of 184 ± 19 min for sc(Fv)₂ and 265 ± 39 min for [sc(Fv)₂]₂ (P < 0.001). At 6 h after administration, the tumor localization was 7.2 ± 0.7 percentage injected dose per gram of tumor (%ID/g) for ^99mTc-sc(Fv)₂. ^99mTc-[sc(Fv)₂]₂ showed a tumor uptake of 19.1 ± 1.1 %ID/g at the same time; the amount of radioactivity in the tumors was 4-fold higher than in the spleen and kidneys and 2-fold higher than in the liver. Macroautoradiography performed at 6 and 16 h after administration clearly detected the tumor with both scFv’s. Conclusion: ^99mTc-labeled multivalent scFv’s show good tumor-targeting characteristics and high radiolocalization indices (tumor-to-background ratio). These reagents, therefore, have the potential for use in clinical imaging studies of cancer in the field of nuclear medicine.

Key Words: single-chain Fv • multivalency • ^99mTc • biodistribution • macroautoradiography

This article has been cited by other articles:

				V. Tolmachev, M. Friedman, M. Sandstrom, T. L.J. Eriksson, D. Rosik, M. Hodik, S. Stahl, F. Y. Frejd, and A. Orlova Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry J. Nucl. Med., February 1, 2009; 50(2): 274 - 283. [Abstract] [Full Text] [PDF]

				J. Shi, Y. Liu, Y. Zheng, Y. Guo, J. Zhang, P.-t. Cheung, R. Xu, and D. Zheng Therapeutic Expression of an Anti-Death Receptor 5 Single-Chain Fixed-Variable Region Prevents Tumor Growth in Mice Cancer Res., December 15, 2006; 66(24): 11946 - 11953. [Abstract] [Full Text] [PDF]

				M. Jain, S. C. Chauhan, A. P. Singh, G. Venkatraman, D. Colcher, and S. K. Batra Penetratin Improves Tumor Retention of Single-Chain Antibodies: A Novel Step toward Optimization of Radioimmunotherapy of Solid Tumors Cancer Res., September 1, 2005; 65(17): 7840 - 7846. [Abstract] [Full Text] [PDF]

				V. Awasthi, G. Meinken, K. Springer, S. C. Srivastava, and P. Freimuth Biodistribution of Radioiodinated Adenovirus Fiber Protein Knob Domain after Intravenous Injection in Mice J. Virol., June 15, 2004; 78(12): 6431 - 6438. [Abstract] [Full Text] [PDF]

				F. A. Jaffer and R. Weissleder Seeing Within: Molecular Imaging of the Cardiovascular System Circ. Res., March 5, 2004; 94(4): 433 - 445. [Abstract] [Full Text] [PDF]

				D. M. Agnese, S. F. Abdessalam, W. E. Burak Jr., M. W. Arnold, D. Soble, G. H. Hinkle, D. Young, M.B. Khazaeli, and E. W. Martin Jr. Pilot Study Using a Humanized CC49 Monoclonal Antibody (HuCC49{Delta}CH2) to Localize Recurrent Colorectal Carcinoma Ann. Surg. Oncol., February 1, 2004; 11(2): 197 - 202. [Abstract] [Full Text] [PDF]

				M. Jain and S. K. Batra Genetically Engineered Antibody Fragments and PET Imaging: A New Era of Radioimmunodiagnosis J. Nucl. Med., December 1, 2003; 44(12): 1970 - 1972. [Full Text] [PDF]

				S. V.S. Kashmiri Multivalent Single-Chain Antibodies for Radioimaging of Tumors J. Nucl. Med., October 1, 2001; 42(10): 1528 - 1529. [Full Text] [PDF]